{"filing":{"accession_number":"0001437749-26-031247","cik":"0001016504","ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"inbp20260925_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/inbp20260925_8k.htm"},"events":[{"id":35204,"run_id":32414,"accession_number":"0001437749-26-031247","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release disclosing quarterly and fiscal year financial results for the period ended June 30, 2026. The press release (Exhibit 99.1) presents condensed consolidated statements of operations showing revenue decline of 19.3% year-over-year, a swing from operating income of $2.0 million to an operating loss of $2.7 million, and a net loss of $2.8 million versus prior-year net income of $0.8 million. The disclosure is material as it reflects significant deterioration in financial performance and would affect a reasonable investor's assessment of the company.","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":39169,"accession_number":"0001437749-26-031247","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing quarterly and fiscal year financial results for the period ended June 30, 2026. The press release (Exhibit 99.1) presents condensed consolidated statements of operations showing revenue decline of 19.3% year-over-year, a swing from operating income of $2.0 million to an operating loss of $2.7 million, and a net loss of $2.8 million versus prior-year net income of $0.8 million. The disclosure is material as it reflects significant deterioration in financial performance and would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T21:09:45.975262+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39169,"accession_number":"0001437749-26-031247","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing quarterly and fiscal year financial results for the period ended June 30, 2026. The press release (Exhibit 99.1) presents condensed consolidated statements of operations showing revenue decline of 19.3% year-over-year, a swing from operating income of $2.0 million to an operating loss of $2.7 million, and a net loss of $2.8 million versus prior-year net income of $0.8 million. The disclosure is material as it reflects significant deterioration in financial performance and would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T21:09:45.975262+00:00","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-09-25"}]}